주식/증권 ➡️ 중립

An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.

MarketWatch - Top Stories 2026/06/01 12:06:00 4회

요약

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug

원문 기사 보기

관련 뉴스

Fortuna reports positive feasibility study for Senegal gold project

U.S. airline stocks are soaring as cheaper jet fuel and insatiable demand set up a summer boom

Bristol, Merck, AbbVie face House committee probe over China trials

The chip rally has a dark side — and a rare market risk is at its highest level since 2015

뉴스 목록으로